Complicated Urinary Tract Infections Treatment Market

Complicated Urinary Tract Infections treatment market Snapshot (2023 to 2033)

The global Complicated Urinary Tract Infections treatment market size is expected to surpass an impressive valuation of USD 9.2 billion in 2023 and is projected to reach USD 16.1 billion by 2033, trailing a CAGR of 5.76%

Due to the increase in drug-resistant bacteria and overuse of antibiotics, the prevalence of complicated urinary tract infections is expected to grow in the future which will fuel the market expansion of complicated urinary tract infection treatment. The increasing prescription of quinolones by doctors to treat complex UTI situations will propel market growth. Also, the use of Cephalosporin as a secondary treatment option will also aid in the market growth.

However, conflicting guidelines on complicated urinary tract infections issued by several organizations cause confusion among providers that will negatively impact the growth of the complicated urinary tract infection treatment market.

Report Attribute	Details
Expected Market Value (2023)	USD 9.2 billion
Anticipated Forecast Value (2033)	USD 16.1 billion
Projected Growth Rate (2023 to 2033)	CAGR 5.76%

2018 to 2022 Complicated Urinary Tract Infections Demand Analysis vs. Forecast 2023 to 2033

The market for complicated urinary tract infection treatment was worth USD 7.6 billion in 2018 while growing at a CAGR of 3.9% during the historical period.

The high demand for antibiotics as they are the only treatment for complicated urinary tract infections and urinary tract infections will transform the market scenario.

There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market which will open up new avenues for the market. Furthermore, increasing mergers, acquisitions, and collaborations between companies to develop safe and effective drugs will drive the complicated urinary tract infections market growth.

Also, for treating complicated urinary tract infections, fluoroquinolones such as ciprofloxacin or ofloxacin are prescribed in case of less severe infection. Apart from these, the loss of patent rights of branded drugs and the availability of cost-effective antibiotics from generic companies are among the factors that are likely to spur the growth of the complicated urinary tract infection treatment market.

After a comprehensive analysis of the above-mentioned factors, the market for complicated Urinary tract infections treatment market is projected to reach USD 16.1 billion by 2033 with a CAGR of 5.76% during the forecast period.

Which are Some Prominent Drivers of the Complicated Urinary Tract Infections treatment market?

The arrival of pipeline therapies to drive market growth

The complicated urinary tract infections therapies in the pipeline include Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime-zidebactam (WCK-5222), Cefepime/Taniborbactam, Cefepime/Enmetazobactam, Fosfomycin (ZT-01/Contempo), Finafloxacin, and others. These therapies are expected to augment the growth of the Complicated urinary tract infections treatment market during the forecast period.

The growth in complicated urinary tract infections market size is also a direct consequence of a rise in research and development activity, a growing prevalent population, and the expected commercial success of upcoming therapies.

With increasing multidrug resistance and antibiotic overuse, the prevalence of complicated urinary tract infections is anticipated to rise in the future, leading to the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for complicated UTIs are expected to aid the complicated urinary tract infections market growth.

What are the Challenges Projected to be Faced by the Market?

High cost and potential side effects to restrain market expansion

Inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus restraining the growth of the complicated urinary tract infections market. Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to hinder clinical trial study evaluation in the complicated urinary tract infections market.

As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis; complex regulatory requirements are anticipated to hamper the growth of the complicated urinary tract infections market.

Region-Wise Insights

What is the growth outlook in North America?

North America to lead the market with the maximum share

The Complicated urinary tract infections treatment market in this region is estimated to grow USD 5.29 billion by 2033, exhibiting a CAGR of 4% during the forecast period. It is estimated to hold a 32.9% industry share by end of the projected period. The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for complicated urinary tract infections which will fuel growth in this region.

Additionally, according to a study published in Therapeutic Advances in Urology in May 2020 titled An Introduction to the Epidemiology and Burden of Urinary Tract Infections, urinary tract infections (UTIs) are the most common outpatient infections in adult women, with a lifetime prevalence of 50-60%. Urinary tract infections are a substantial societal and personal burden, with complicated urinary tract infections accounting for a significant number of medical visits in the US each year. This condition is estimated to drive the market by increasing sales of urinary tract infection medicines in the region.

On the other hand, research, and development of novel classes of antibiotics for urinary tract infections are anticipated to aid in market expansion. In August 2020, for example, researchers at California Polytechnic State University announced the development of a new class of antibiotics for urinary tract infections that target bacterial iron acquisition.

Thus, all the above factors are expected to propel growth in the region during the forecast period.

What is the growth prospect in East Asia?

East Asia propelling growth at fastest CAGR

The market in East Asia is projected to be worth USD 3.2 billion by 2033 while growing at a CAGR of 5.1% during the forecast period. This region is estimated to account for around 20% market share by end of the forecast period. The growth is attributable to high investments in research and development departments by key players to combine and launch new medications that are tailored to the needs of the East-Asian market. Growth in the prevalence of hospital-acquired UTIs and technological advancements in testing instruments will drive growth. Furthermore, excellent reimbursement conditions and illness management will boost market expansion.

Category wise Insights

By drug class, which segment will witness the fastest growth

Penicillin and combinations to reflect growth with the fastest CAGR

The penicillin and Combinations Segment is projected to grow with the fastest compounded annual growth rate of 7.9% during the forecast period. The growth is attributed to the rising prevalence of urinary tract infections (UTIs). Most penicillin’s widely being used directly and in combinations for treating urinary tract infections that are augmenting the segment’s growth.

Which segment will possess market hegemony by the drug class?

Quinolones fuelling segments growth with maximum share

This segment is estimated to hold around 48.6% market share by end of the forecast period. The growth is attributed to the surge in demand for novel UTI therapeutics. Quinolones represent a natural alternative to trimethoprim-sulfamethoxazole for treating urinary tract infections (UTIs) when resistance becomes a potential problem. Quinolones are broadly active against most Gram-negative and Gram-positive organisms, so that multi-drug resistance is avoided in the treatment of urinary tract infections. Thus, driving the segment’s growth.

Also, these drugs have the capability to improve quality of life and combat symptoms with high therapeutic effects. These lifesaving advantages of quinolones make them the most profitable and highly adopted products across regions that fuel the growth of the overall market.

By distribution channel, which segment will account for the maximum share?

Hospital pharmacies lead the segment with dominating share

This segment is estimated to dominate the market with a maximum market share of 51% by end of the forecast period. The growth is attributable to high investments in hospital infrastructure and faster adoption of various novel drugs for the treatment of complicated urinary tract infections.

Start-ups in Complicated Urinary Tract Infections treatment market

• Founded in 2016, ‘ODx innovations’ is a United Kingdom-based start-up that provides rapid antibiotic susceptibility testing for Urinary Tract Infections (UTI). The company offers antimicrobial resistance and microbiological technology to diagnose bacterial infection and bacterial count in UTIs and provide antibiotic sensitivities of the isolated pathogen for treatment.
• Founded in 2015, Biomedicals is a Molndal, Sweden-based start-up that develops smart medical devices for treating urinary tract infections. The company has developed a UTI-Q orally administered medical device that reduces the presence of E. Coli bacteria in adult people with urinary tract infections.
• Founded in 2011, ‘Ideal Medical Solution’ is an Epsom, United Kingdom-based start-up that provides ultrasound nano-technology to prevent catheter-associated urinary tract infections. Its flagship product UroShield is an external medical device developed to prevent bacterial biofilm formation on urethral and suprapubic catheters by means of nonharmful ultraviolet rays.

Market Competition

The global Complicated Urinary Tract Infections treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allegra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, Allergan, Bayer AG, Pfizer, Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC

Some recent developments in this industry are:

• In November 2020, Allergan announced the FDA acceptance of a Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
• In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
• In September 2021, BDR Pharma, one of India's leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 9.2 billion
Market Value in 2033	USD 16.1 billion
Growth Rate	CAGR of 5.76% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	By drug, By distribution channel, By Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Profiled	United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, UAE, South Africa, Israel, GCC countries
Key Companies Profiled	Spero Therapeutics; Wockhardt; Venatorx Pharmaceuticals; Allecra Therapeutics; Nabriva Therapeutics AG; MerLion Pharmaceuticals; Allergan; Bayer AG; Pfizer, Inc; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Janssen Global Services, LLC
Customization	Available Upon Request

Key Segments Profiled in the Complicated Urinary Tract Infections treatment market Industry survey

Complicated Urinary Tract Infections treatment market by Drug class:

• Penicillin and combinations
• Quinolones
• Cephalosporin
• Azoles and Amphotericin B
• Nitro furans

Complicated Urinary Tract Infections treatment market by Distribution channel:

• Hospital Pharmacies
• Gynecology and Urology Clinics
• Drug stores
• Retail Pharmacies

Complicated Urinary Tract Infections treatment market by Region::

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

What are the Key Opportunities in the Complicated Urinary Tract Infections Treatment Market?

The rising need for innovative antibiotics, and expanded healthcare infrastructure are some important potentials.

What Insights can be Drawn from the cUTI Treatment Market?

Increase in the occurrence of infections that are resistant to treatment and the need for shorter treatment times.

Which Segment is Leading in the cUTI Treatment Market?

Due to their proven efficacy, antibiotics continue to be a prominent sector.

What are the Emerging Trends in the cUTI Treatment Market?

The creation of non-antibiotic substitutes and use of artificial intelligence in medication research are recent trends.

How are Market Dynamics Influencing Cuti Treatment Trends?

Increased R&D investments and collaborations are being driven by market dynamics.